Abstract:Background: Solid tumors need new blood vessels to feed and nourish them as well as to allow tumor cells to escape into the circulation and lodge in other organs, which is termed "angiogenesis." Some tumor cells within solid tumors can overexpress integrins alpha(v)beta(3) and alpha(v)beta(5), which can specifically recognize the peptide motif Arg-Gly-Asp (RGD). Thus, the targeting of RGD-modified micelles to tumor vasculature is a promising strategy for tumor-targeting treatment.Methods: RGD peptide (GSSSGRGDSPA) was coupled to poly(ethylene glycol)-modified stearic acid-grafted chitosan (PEG-CS-SA) micelles via chemical reaction in the presence of N,N'-Disuccinimidyl carbonate. The critical micelle concentration of the polymeric micelles was determined by measuring the fluorescence intensity of pyrene as a fluorescent probe. The micelle size, size distribution, and zeta potential were measured by light scattering and electrophoretic mobility. Doxorubicin (DOX) was chosen as a model anticancer drug to investigate the drug entrapment efficiency, in vitro drug-release profile, and in vitro antitumor activities of drug-loaded RGD-PEG-CS-SA micelles in cells that overexpress integrins (alpha(v)beta(3) and alpha(v)beta(5)) integrin-deficient cells.Results: Using DOX as a model drug, the drug encapsulation efficiency could reach 90%, and the in vitro drug-release profiles suggested that the micelles could be used as a controlled-release carrier for the hydrophobic drug. Qualitative and quantitative analysis of cellular uptake indicated that RGD-modified micelles could significantly increase the DOX concentration in integrin-overexpressing human hepatocellular carcinoma cell line (BEL-7402), but not in human epithelial carcinoma cell line (Hela). The competitive cellular-uptake test showed that the cellular uptake of RGD-modified micelles in BEL-7402 cells was significantly inhibited in the presence of excess free RGD peptides. In vitro cytotoxicity tests demonstrated DOX-loaded RGD-modified micelles could specifically enhance the cytotoxicity against BEL-7402 compared with DOX-loaded PEG-CS-SA and doxorubicin hydrochlorate.Conclusion: This study suggests that RGD-modified PEG-CS-SA micelles are promising drug carriers for integrin-overexpressing tumor active targeting therapy.

A D-Peptide Ligand of Integrins for Simultaneously Targeting Angiogenic Blood Vasculature and Glioma Cells

Liposome-Based Systemic Glioma-Targeted Drug Delivery Enabled by All-d Peptides.

Stable Peptides Mediated Glioma Targeting Drug Delivery

A novel peptide-drug conjugate for glioma-targeted drug delivery

Substance P Mediated DGLs Complexing with DACHPt for Targeting Therapy of Glioma

D-Retroenantiomer of Quorum-Sensing Peptide-Modified Polymeric Micelles for Brain Tumor-Targeted Drug Delivery

Tumor Microenvironment and Angiogenic Blood Vessels Dual-Targeting for Enhanced Anti-Glioma Therapy.

Potent retro-inverso D-peptide for simultaneous targeting of angiogenic blood vasculature and tumor cells.

Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma

GRP78 Enabled Micelle-Based Glioma Targeted Drug Delivery.

Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery

Tumor-penetrating Peptide Functionalization Enhances the Anti-Glioblastoma Effect of Doxorubicin Liposomes.

Ɑvβ3-Targeted Liposomal Drug Delivery System with Attenuated Immunogenicity Enabled by Linear Pentapeptide for Glioma Therapy

All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide

RGD Peptide-Mediated Chitosan-Based Polymeric Micelles Targeting Delivery for Integrin-Overexpressing Tumor Cells.

RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells.

Enhanced glioma-targeting and stability of L GICP peptide coupled with stabilized peptide D A7R.

Tumor-targeting Dual Peptides-Modified Cationic Liposomes for Delivery of Sirna and Docetaxel to Gliomas.

Peptide-22 and Cyclic Rgd Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming Bbb and Bbtb

Glioma-Targeted Drug Delivery Enabled by A Multifunctional Peptide

iNGR-Modified Liposomes for Tumor Vascular Targeting and Tumor Tissue Penetrating Delivery in the Treatment of Glioblastoma